AWA
DNA icon

Amplius Wealth Advisors’s Ginkgo Bioworks DNA Stock Holding History

Amplius Wealth Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-90
Closed -$29K – 354
2021
Q4 		$29K Buy
+90
New +$42.8K ﹤0.01% 411

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Amplius Wealth Advisors's DNA Position: Q1 2022 in Review

Amplius Wealth Advisors sold out of Ginkgo Bioworks (DNA) in Q1 2022, closing a stake of 90 shares — an estimated $29K sold.

Amplius Wealth Advisors first reported a position in DNA in Q4 2021 and held it in 1 quarter. The position peaked at $29K in Q4 2021. 190 funds tracked by Wall St. Rank hold DNA as of Q1 2022.

  • Amplius Wealth Advisors reported no remaining Ginkgo Bioworks position as of Q1 2022 after selling out during the quarter.
  • Amplius Wealth Advisors sold 90 Ginkgo Bioworks shares in Q1 2022, an estimated $29K.
  • Amplius Wealth Advisors first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 1 quarter.
  • Amplius Wealth Advisors's Ginkgo Bioworks position peaked at $29K in Q4 2021.
  • 190 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2022.

Based on Amplius Wealth Advisors's 13F filing for Q1 2022, filed 9 May 2022.